<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822483</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080</org_study_id>
    <secondary_id>CERL080ABR08T</secondary_id>
    <nct_id>NCT01822483</nct_id>
  </id_info>
  <brief_title>A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)</brief_title>
  <acronym>AUC-MPA</acronym>
  <official_title>A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Irmandade Santa Casa de Misericórdia de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is investigate mycophenolic acid exposure through area under the
      curve in renal transplants recipients treated with mycophenolate mofetil and after conversion
      to mycophenolate sodium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A growing body of evidence has shown that mycophenolate acid (MPA) exposure assessment and
      dosage adjustment are necessary in patients treated with mycophenolate mofetil (MMF), but
      there is still limited information about the dose-exposure-effect relationship of the
      enteric-coated mycophenolate sodium (EC-MPS) formulation that has quite different
      physicochemical properties (TETT et al., 2011).

      Pharmacokinetically guided exposure-controlled area under the concentration-time curve (AUC)
      approaches are helpful to limit interpatient variability of MPA exposure and to improve the
      clinical outcome of organ transplant recipients (TETT et al., 2011).

      MPA area under the concentration-time curve values between 30 and 60 μg h/mL in the early
      post-transplant period reduces the risk of acute rejections and seems to be appropriate in
      renal allograft recipients taking mycophenolate sodium (MPS) and calcineurin inhibitors
      (GRINYÓ et al., 2009; SOMMERER et al., 2010).

      Among the benefits of therapeutic drug monitoring of MPA are the evaluation of interaction
      between MPA and proton pump inhibitors and association of donor-specific antibodies
      reduction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the frequency of renal transplants recipients taking mycophenolate mofetil (MMF) with MPA AUC below target level (30mcg*h ml-1).</measure>
    <time_frame>Baseline</time_frame>
    <description>Evaluate the frequency of renal transplants recipients taking mycophenolate mofetil (MMF) with MPA AUC below target level (30mcg*h ml-1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the association of MPA AUC in renal transplant recipients with donor specific antibodies (DSA);</measure>
    <time_frame>Baseline; month 6.</time_frame>
    <description>Evaluate the association of MPA AUC in renal transplant recipients with donor specific antibodies (DSA);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the interaction between MMF or EC-MPS and the proton pump inhibitor omeprazole through the AUC in patients with MPA below target level (30mcg*h ml-1).</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the interaction between MMF or EC-MPS and the proton pump inhibitor omeprazole through the AUC in patients with MPA below target level (30mcg*h ml-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the association of MPA AUC with renal function estimated by MDRD formula.</measure>
    <time_frame>Baseline; day one; months 2, 4 and 6.</time_frame>
    <description>Evaluate the association of MPA AUC with renal function estimated by MDRD formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the MPA_AUC in renal transplant patients converted to mycophenolate sodium (MPS) with equivalent dose of mycophenolate mofetil (MMF).</measure>
    <time_frame>Baseline, five days after day one, fourteen days after day one, months 2,4 and 6</time_frame>
    <description>Evaluate the MPA_AUC in renal transplant patients who were taking mycophenolate mofetil (MMF) and were converted to the use of mycophenolate sodium (MPS) by having the MPA concentration below the target level of 30 mcg*h ml-1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the MPA_AUC in renal transplant patients maintained with mycophenolate mofetil (MMF).</measure>
    <time_frame>baseline, months 2,4 and 6</time_frame>
    <description>Evaluate the AUC_MPA in renal transplant patients maintained with mycophenolate mofetil(MMF) by having the MPA concentration between 30-60 mcg*h ml-1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Mycophenolate sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm1(Conversion):MPA AUC below 30mcg*h ml-1 - MPS+Calcineurin inhibitor+prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm2(Maintained):MPA AUC between 30 to 60 mg*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate sodium</intervention_name>
    <description>The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.</description>
    <arm_group_label>Mycophenolate sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg*h ml-1.</description>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years at the time of screening;

          -  Subjects above the sixth month post renal transplant;

          -  Subjects receiving mycophenolate mofetil;

          -  Women of childbearing potential (CBP) with a negative pregnancy test at screening
             (urine or serum);

          -  Women of CBP and men with sexual partners of CBP must agree to use a medically
             acceptable method of contraception throughout the study.

        Exclusion Criteria:

          -  Subjects who, in the opinion of the investigator, are not able to complete the study;

          -  Recipients of multiple organ transplant (i.e., prior or concurrent transplantation of
             a non-renal allograft;

          -  Use of any investigational drug or treatment up to 4 weeks before enrollment;

          -  Subjects with a calculated GFR &lt; 30ml/min (abbreviated MDRD formula);

          -  Subjects with a screening total white blood cell count (WBC) ≤ 2000/mm3, hemoglobin ≤
             10g/dL and platelet count ≤ 100000/mm3;

          -  TGO/AST, TGP/ALT and bilirubin with values three times higher that reference values;

          -  History of malignancy within 3 years enrollment other than adequately treated basal
             cell or squamous cell carcinoma of the skin;

          -  Subjects who are known to be human immunodeficiency virus (HIV), hepatitis B or
             hepatitis C;

          -  Chronic hepatic failure;

          -  Planned treatment with immunosuppressive therapies other than those described in the
             protocol;

          -  Recipients who required desensitization protocols.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valter Garcia, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizete Keitel, Physician</last_name>
    <role>Study Chair</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela Seelig, Physician</last_name>
    <role>Study Chair</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRIDA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabiano Klaus, Physician</last_name>
    <role>Study Chair</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRIDA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronivan Dal Pra, Pharmacist</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larissa Pacheco, Pharmacist</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruna Cardoso, Pharmacist</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Kist, Trainee</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Zanetti, Pharmacist</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irmandade Da Santa Casa de Misericórdia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90020090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001. Epub 2010 Dec 28.</citation>
    <PMID>21190834</PMID>
  </reference>
  <reference>
    <citation>Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant. 2009 Jul;24(7):2269-76. doi: 10.1093/ndt/gfp162. Epub 2009 Apr 8.</citation>
    <PMID>19357111</PMID>
  </reference>
  <reference>
    <citation>Sommerer C, Müller-Krebs S, Schaier M, Glander P, Budde K, Schwenger V, Mikus G, Zeier M. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol. 2010 Apr;69(4):346-57. doi: 10.1111/j.1365-2125.2009.03612.x.</citation>
    <PMID>20406219</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2013</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Irmandade Santa Casa de Misericórdia de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Valter Duro Garcia</investigator_full_name>
    <investigator_title>PHYSICIAN NEPHROLOGY</investigator_title>
  </responsible_party>
  <keyword>Renal transplantation</keyword>
  <keyword>mycophenolic acid</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>mycophenolate sodium</keyword>
  <keyword>area under the curve</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

